Showing results (1-10 of 360) with videos related to
Sort By:
Pageof 36
Future Oncology (London, England)|June 3, 2025
DNAJA: emerging targets for anti-tumor therapyLige Wu, Puyuan Xing, Junling LiJournal of Translational Medicine|June 20, 2024
Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIsLige Wu, Zihua Zou, Yan Li, et al.Thoracic Cancer|March 20, 2026
TP53 CpG Site Mutations Predict the Survival of First-Line Chemoimmunotherapy in Advanced Lung AdenocarcinomaLige Wu, Zihua Zou, Yan Li, et al.Thoracic Cancer|January 22, 2025
Impact of EML4-ALK Variants and TP53 Status on the Efficacy of ALK Inhibitors in Patients With Non-small Cell Lung CancerZihua Zou, Lige Wu, Xuezhi Hao, et al.Cancer Innovation|December 13, 2023
PD-L1 blockade by immune checkpoint inhibitors impairs sensitivity to osimertinib in EGFR-mutant non-small cell lung cancer cellsDantong Sun, Puyuan Xing, Junling LiZhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|October 21, 2016
[Treatment of Advanced Squamous Cell Lung Cancer]Yixiang Zhu, Puyuan Xing, Junling LiZhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|October 12, 2013
[Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small cell lung cancer]Puyuan Xing, Junling Li, Yuankai ShiTranslational Lung Cancer Research|February 9, 2026
Efficacy and safety of lorlatinib in first-line and subsequent-line treatments for patients with ALK-positive non-small cell lung cancer: a single-center real-world study in ChinaLige Wu, Jiayu Liu, Zihua Zou, et al.Signal Transduction and Targeted Therapy|July 23, 2026
Mechanisms and therapeutic targets in distant metastasis of lung adenocarcinomaTongji Xie, Lige Wu, Yan Li, et al.Frontiers in Oncology|November 21, 2022
Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysisPuyuan Xing, Xuezhi Hao, Xin Zhang, et al.Pageof 36